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Abstract It was reported that nicotine-induced dopamine
release in the rat pheochromocytoma cell line, PC12 cells, was
inhibited by U-opioid. However, it is not known whether
inhibition of catecholamine biosynthesis is involved in the
inhibitory mechanisms of U-opioids in PC12 cells. U-69593 (a
U-opioid agonist: v100 nM) significantly inhibited the nicotine-
induced increase of tyrosine hydroxylase (TH, a rate-limiting
enzyme in biosynthesis of catecholamine) enzyme activity and
TH mRNA levels. These inhibitory effects were completely
reversed by naloxone and nor-binaltorphimine dihydrochloride
(nor-BNI), a specific U-antagonist, whereas pertussis toxin
(PTX) only partially reversed this inhibitory effect. Also, U-
69593 (v100 nM) significantly inhibited the nicotine-induced
increase of cAMP production. This inhibitory effect was
completely reversed by naloxone and nor-BNI, whilst only
partially reversed by PTX. Moreover, U-69593 (v100 nM)
significantly inhibited the nicotine-induced increase of both the
TH protein level and intracellular catecholamine levels. These
results indicate that the anti-cholinergic actions of U-opioid can
be explained partially by its inhibition of both TH enzyme
activity and TH synthesis, through suppression of the cAMP/
protein kinase A pathway. It would also appear that the PTX-
sensitive G-protein mediates the inhibitory effect of this pathway,
at least in part. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Adrenal chroma⁄n cells produce opioids as well as cate-
cholamine [1^4]. The biological e¡ects of opioids are believed
to be mediated via speci¢c receptors (U, N and W), which be-
long to the family of GTP binding protein (G-protein)-
coupled receptors [5]. It was demonstrated that stimulation
of these opioid receptors leads to inhibition of adenylate-cy-
clase (AD) through pertussis toxin (PTX)-sensitive G-protein
(Gi=o), resulting in the reduction of cAMP levels [6,7].
Although the precise role of opioids in chroma⁄n cells is
unclear, growing evidence suggests that opioids exert their
action through the inhibition of catecholamine release in a
paracrine and/or autocrine manner. Normal adrenal chromaf-
¢n cells produce only N-opioid peptides such as enkephalin,
which inhibit basal and nicotine-induced catecholamine secre-
tion [2,4,8,9]. This property of normal chroma⁄n cells may be
changed as a result of their transformation to pheochromocy-
tomas. Indeed, human pheochromocytomas produce U-opioid
peptides such as dynorphin in addition to enkephalin and
have a U-opioid binding site [10^12]. Furthermore, Margioris
et al. [3] demonstrated that PC12 cells, a rat pheochromocy-
toma cell line, which is an appropriate model to investigate
pheochromocytomas, contain and secrete dynorphin in addi-
tion to enkephalin [1,3]. Moreover, it was demonstrated in
several studies that U-opioid agonists, but not N- or W-opioid
agonists, signi¢cantly inhibited nicotine-induced dopamine re-
lease in PC12 cells [13,14]. These ¢ndings indicate that
U-opioids are the most potent inhibitors of catecholamine re-
lease in PC12 cells. However, it is unclear whether inhibition
of catecholamine biosynthesis is involved in the anti-choliner-
gic e¡ect of U-opioids in PC12 cells.
In adrenal medullary cells, tyrosine hydroxylase (TH) is a
rate-limiting enzyme in the biosynthesis of catecholamine. TH
activity can be regulated by both short- and long-term mech-
anisms. Short-term regulation of enzyme activity occurs at the
post-transcriptional level. Central to this regulation is the
phosphorylation of TH, which results in activation of the
enzyme [15]. Indeed, TH is phosphorylated and activated by
a variety of protein kinases including cAMP protein kinase A
(PKA) [16^18]. A long-term regulation has been shown to be
exerted at the TH protein synthesis level following TH gene
transcription [19]. Similar to their e¡ect on TH enzyme activ-
ity, several protein kinases, including PKA, also induce an
increase in levels of TH mRNA [19].
Nicotine is a ligand of the nicotinic acetylcholine receptor
in adrenal medullary cells. Both TH enzyme activity and TH
mRNA are increased by nicotine treatment in the rat pheo-
chromocytoma cell line, PC12 [15,20]. Moreover, the cAMP-
mediated pathway appears to play a key role in both the
nicotine-induced TH enzyme activity and TH mRNA levels
[20].
To gain new insight into the mechanisms underlying the
anti-cholinergic action of opioids, we investigated the e¡ects
of opioids on nicotine-stimulated catecholamine biosynthesis
in PC12 cells.
2. Materials and methods
2.1. Reagents
Unless otherwise noted, all reagents were purchased from Wako
Seiyaku (Tokyo, Japan). U-69593, DPDPE and DAGO (U-, N- and
W-opioid agonists, respectively), nor-binaltorphimine dihydrochloride
(nor-BNI: a speci¢c U-antagonist) were purchased from Sigma Chem-
ical (St. Louis, MO, USA). The concentrations of U-agonist, U-69593,
used in our experiments (1 nM^1 WM) were chosen according to
Venihaki et al. [13,21]. Toxicity of U-69593 to PC12 cells was negli-
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gible under our experimental conditions [21]. The concentration of
nor-BNI was set at 100 nM according to Venihaki et al. [21].
2.2. Cell culture
The PC12 cell line (RCB009) was obtained from the RIKEN Cell
Bank (Ibaraki, Japan). Cells were grown in 75 cm2 £asks in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) (Gibco BRL, Gaithersburg,
MD, USA) containing 10% inactivated horse serum (Gibco BRL) and
10% fetal bovine serum (Gibco BRL) in a humidi¢ed atmosphere of
5% CO2/95% O2 at 37‡C. The culture medium was changed three
times per week. Cells were removed from the £asks for subculture
and for plating into assay dishes using a Ca2/Mg2-free solution of
172 mM NaCl, 5.4 mM KCl, 1 mM NaH2PO4 and 5.6 mM glucose,
at pH 7.4. After about 2 min in this solution, the cells were detached
by tapping the side of the £ask. The cells (1U106) were plated into
35 mm polystyrene dishes and cultured with 2 ml of DMEM for 2 days
under similar conditions as described above, and then used for experi-
ments in a serum-starved condition.
2.3. TH enzyme activity
TH enzyme activity was measured using a method previously re-
ported by Kumai et al. [22]. Experiments were initiated by replacing
the medium with HEPES-bu¡ered Krebs bu¡er containing various
concentrations (10 nM^1 WM) of U-69593 or U-69593 (1 WM) in
the presence of PTX (100 ng/ml) or naloxone (1 M) or nor-BNI
(100 nM), and the cells were incubated at 37‡C for 10 min. Then,
cells were homogenized in 0.25 M sucrose (50 volumes) using a glass
tissue grinder. The standard incubation medium consisted of the fol-
lowing components in a total volume of 250 Wl : 100 Wl tissue homo-
genate, 40 Wl of 1 M sodium acetate bu¡er (pH 6.0), 40 Wl of 1 mM
L-tyrosine or D-tyrosine, 20 Wl of 1 M 6-methyl-5,6,7,8-tetra-hydro-
pterine in 1 M 2-mercaptoethanol, 20 Wl of 20 mM catalase and 30 Wl
water. The medium was incubated at 37‡C for 30 min, and the reac-
tion stopped with 1 M perchloric acid containing dihydroxy benzyl-
amine as an internal standard and then 0.2 M EDTA in an ice bath.
Then, 1 M potassium carbonate and 0.2 M Tris^HCl (pH 8.5) con-
taining 1% EDTA were added. The 3-(3,4-di-dihydroxyphenyl)-ala-
nine (DOPA) was extracted using the aluminum oxide method. 40 Wl
of extracted medium was mixed with 0.1 N NaOH and TSK-GEL
ODS-120T (TOSOH, Japan) and analyzed by high performance liquid
chromatography (HPLC). The mobile phase consisted of the follow-
ing components: 50 mM sodium acetate, 20 mM citric acid, 12.5 mM
sodium octyl sulfate, 1 mM di-n-butylamine and 0.134 mM EDTA.
All separations were performed isocratically at a £ow rate of
0.6 ml/min at 28‡C. The detector potential was maintained at
+0.65 V. The TH enzyme activity was calculated as the amount of
DOPA formed from tyrosine per mg of protein per minute.
2.4. Northern blot analysis
For Northern blot analysis, total RNA was extracted from the
samples using an ISOGEN kit (Nippon Gene, Tokyo, Japan). The
RNA concentration was determined spectrophotometrically (at
260 nm). RNA (10 Wg sample) was fractionated by electrophoresis
on 1% agarose/5% formaldehyde gels (80 V, 2 h). After staining
with ethidium bromide and a visual inspection of the UV £uorescence
to con¢rm the presence of equal amounts of 18S and 28S ribosomal
RNA in each lane, the RNA was transferred to a nitrocellulose mem-
brane and hybridized to 32P-labeled probes. The following probe was
used: a 1.9 kbp EcoRI fragment of pTHT1 encoding TH. Plasmid
pTHT1 contained the full-length cDNA for human TH type 1 cDNA.
This plasmid was developed by T. Nagatsu and was provided by the
RIKEN Gene Bank (Ibaraki, Japan). The probe was labeled using a
random primer extension labeling kit (New England Nuclear, Boston,
MA, USA). Rat G3PDH cDNA was used as an internal standard
(Clontech, Palo Alto, CA, USA). Hybridization signals were scanned
in an image analyzer (BAS2000, Fuji, Tokyo).
2.5. Western blot analysis
Western blot analyses were performed as previously described [23].
In brief, the cells were solubilized with 0.1% sodium dodecyl sulfate
(SDS) containing 1% Triton X-100, 1% sodium deoxycholate and
20 mM Tris^HCl, pH 7.4. The supernatant containing 10 mg protein
was separated on 10% SDS^polyacrylamide gels, and then transferred
to nitrocellulose using a Bio-Rad Transblot apparatus. After transfer,
the nitrocellulose sheets were incubated for 1 h with BLOTTO bu¡er
(5% skimmed milk, 0.05% Triton X-100, 100 mM NaCl, 200 mM
Tris^HCl, pH 7.4). The nitrocellulose membranes were washed three
times for 10 min with TBST solution (0.05% Triton X-100, 20 mM
Tris^HCl, pH 7.4, 150 mM NaCl), and then for 1 h with 1 mg/ml of
the monoclonal antibody to TH (Boehringer, Germany). The nitro-
cellulose membranes were then washed three times for 10 min with
TBST solution, and then incubated for 1 h with horseradish peroxi-
dase-labeled Protein A (Amersham, UK). Finally, the blots were
washed three times, incubated with ECL reagent (Amersham, UK)
for 1 min and then exposed to Polaroid ¢lms (ISO 3000).
2.6. Measurement of cAMP production
The cAMP production by the cells was determined as previously
described [24]. Brie£y, cells were washed twice with EM (Eagle’s min-
imal essential medium) and preincubated in EM containing 0.2 mM
3-isobutyl-1-methylxanthine (IBMX) for 5 min. Experiments were ini-
tiated by replacing the medium with HEPES-bu¡ered Krebs bu¡er
containing test substances and 0.2 mM IBMX, and the cells were
then incubated at 37‡C for 10 min. The reaction was terminated by
adding 100 Wl of l N HCl, followed by incubation on ice for 30 min.
The cAMP in the acid extract was then measured with a cAMP kit
(Yamasa, Chousi, Japan).
2.7. Determination of intracellular catecholamine levels
Cells were treated with U-69593 (10 nM^1 WM) for 24 h. Then, the
catecholamine levels in cells were determined as previously described
[24], using a catecholamine autoanalyzer (TOSOH, H8030, Japan)
with built in HPLC and a spectro£uorometer.
2.8. Statistical analysis
All data are expressed as mean þ S.D. The signi¢cance of di¡erences
in the data was determined by an analysis of variance (ANOVA).
P values less than 0.05 were considered signi¢cant.
3. Results
3.1. E¡ect of U-69593 (U-opioid agonist) on nicotine-induced
TH enzyme activity
As shown in Fig. 1, 10 nM of U-69593 (U-opioid agonist)
had no e¡ect on TH enzyme activity. At 100 nM and over
(100 nM and 1 WM), U-69593 signi¢cantly inhibited the nic-
otine-induced increase of the TH enzyme activity by 24 and
57%, respectively. This inhibitory e¡ect was completely abol-
ished by naloxone and nor-BNI, a speci¢c U-antagonist, sug-
gesting that a U-opioid receptor was involved in the inhibitory
e¡ect of U-69593. Pretreatment of PC12 with 100 ng/ml PTX
for 15 h [25] partially prevented the inhibitory e¡ect of U-
69593. DPDPE and DAGO (N- and W-opioid agonists, respec-
tively) did not alter the nicotine-induced TH enzyme activity
(data not shown).
3.2. E¡ect of U-69593 (U-opioid agonist) on nicotine-induced
TH mRNA expression
As shown in Fig. 2, 10 nM of U-69593 had no e¡ect on the
Table 1
E¡ects of U-69593 on intracellular catecholamine content
Nicotine (WM) U-69593 Dopamine (ng/mg protein)
10 none (control) 1651 þ 50
10 10 nM 1511 þ 62
10 100 nM 1371 þ 78*
10 1 WM 1099 þ 81*
PC12 cells were treated with U-69593 (10 nM^1 WM) for 24 h.
Then, intracellular catecholamine levels (dopamine) were measured
as described in Section 2. Since the major catecholamine synthesized
in PC12 cells is dopamine and the production of noradrenaline and
adrenaline was negligible, ¢ndings on dopamine levels are presented.
Control experiments were done with nicotine (10 WM) alone. *Sig-
ni¢cantly di¡erent (P6 0.05) from controls.
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TH mRNA level. At 100 nM and over (100 nM and 1 WM),
U-69593 signi¢cantly inhibited the nicotine-induced increase
of TH mRNA levels by 37 and 63%, respectively. This inhib-
itory e¡ect was completely abolished by naloxone and nor-
BNI, whereas PTX partially prevented this inhibitory e¡ect of
U-69593. DPDPE and DAGO did not alter the nicotine-in-
duced TH mRNA levels (data not shown).
3.3. E¡ect of U-69593 (U-opioid agonist) on nicotine-induced
cAMP production
Since the increase of cAMP plays a key role in the nicotine-
induced TH activity as well as the TH mRNA level, we next
examined the e¡ect of U-69593 on nicotine-induced cAMP
production. As shown in Fig. 3a, 1 and 10 nM of U-69593
had no e¡ect on the cAMP level. At 100 nM and over (100
nM and 1 WM), U-69593 signi¢cantly inhibited the nicotine-
induced increase of the cAMP production by 34 and 58%,
respectively. Similar to their e¡ect on the TH enzyme activity
and the TH mRNA level, naloxone and nor-BNI completely
abolished the inhibitory e¡ect of U-69593 on cAMP, while
PTX only partially prevented the inhibition (Fig. 3b). In con-
trast to U-69593, DPDPE and DAGO, N- and W-opioid ago-
nists, respectively, did not a¡ect the nicotine-induced cAMP
production.
3.4. E¡ects of U-69593 (U-opioid agonist) on the
nicotine-induced TH protein level and intracellular
catecholamine levels
To con¢rm the decrease of catecholamine synthesis follow-
ing TH mRNA reduction, the e¡ects of U-69593 on the TH
protein level and intracellular catecholamine levels were exam-
ined. PC12 cells were treated with U-69593 (10 nM^1 WM) for
24 h. Then, TH protein and intracellular catecholamine levels
were examined by Western blot analysis and HPLC, respec-
tively. As shown in Fig. 4, 10 nM of U-69593 had no e¡ect on
the TH protein level. At 100 nM and over (100 nM and 1 WM),
U-69593 signi¢cantly inhibited the nicotine-induced increase
of TH protein by 24 and 44%, respectively. Also, as shown in
Table 1, 10 nM of U-69593 had no e¡ect on intracellular
catecholamine levels. At 100 nM and over (100 nM and
1 WM), U-69593 signi¢cantly inhibited the nicotine-induced
increase of intracellular catecholamine levels by 18 and 34%,
respectively.
4. Discussion
The results of the present study showed that the nicotine-
induced increases of both TH enzyme activity and the TH
Fig. 2. E¡ect of U-69593 (U-opioid agonist) on nicotine-induced TH
mRNA expression. (a) PC12 cells were incubated for 8 h with vari-
ous concentrations (10 nM^1 WM) of U-69593, U-69593 (1 WM) in
the presence of PTX (100 ng/ml) or naloxone (1 WM) or nor-BNI
(100 nM), as indicated. Total cellular RNA (10 Wg/lane) from por-
cine adrenal medullary cells was characterized by Northern blot
analysis as described in Section 2. The lower panel shows the con-
trol mRNA (G3PDH) containing equivalent amounts of total
mRNA. Values from duplicate determinations are shown. Control
experiments were done with nicotine (10 WM) alone. (b) The values
represent the means þ S.D. (n = 4) of the radioactivity (photostimu-
lated luminescence minus background) of each TH mRNA level.
*Signi¢cantly di¡erent (P6 0.05) from controls.
Fig. 1. E¡ect of U-69593 (U-opioid agonist) on nicotine-induced TH
enzyme activity. PC12 cells were incubated for 10 min with various
concentrations (10 nM^1 WM) of U-69593, U-69593 (1 WM) in the
presence of PTX (100 ng/ml) or naloxone (1 WM) or nor-BNI
(100 nM), as indicated. Then, TH enzyme activity was measured as
described in Section 2. The values represent the means þ S.D.
(n = 4). Control experiments were done with nicotine (10 WM) alone.
*Signi¢cantly di¡erent (P6 0.05) from controls.
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mRNA level were attenuated by U-69593 (U-opioid agonist)
in parallel (Figs. 1 and 2). This suggests that an inhibitory
e¡ect on catecholamine biosynthesis may be involved in the
anti-cholinergic action of U-opioids. In addition, we demon-
strated that U-69593 markedly suppressed the increase of TH
protein levels induced by nicotine (Fig. 4). Therefore, it is
likely that U-69593 induced a reduction in TH gene expres-
sion, resulting in a decrease of the TH protein level in PC12
cells. Furthermore, we showed that U-69593 markedly sup-
pressed intracellular catecholamine levels (Table 1), support-
ing the suggestion that U-opioid stimulation inhibits catechol-
amine biosynthesis.
It was also shown in the present study that U-69593 inhib-
ited the nicotine-induced increase of cAMP production (Fig.
3a). Moreover, it was noteworthy that this inhibition occurred
at the same threshold concentration of U-69593 (100 nM) as
the inhibition of the nicotine-induced increase of TH mRNA
levels and TH enzyme activity. This would suggest that the
inhibitory e¡ect of U-69593 on the nicotine-induced increase
of TH enzyme activity and TH mRNA levels are mediated, at
least in part, by the cAMP/PKA pathway.
U-69593 markedly suppressed the nicotine-induced increase
of cAMP production, and this inhibitory e¡ect was partially
abolished by pretreatment with PTX (Fig. 3b). These ¢ndings
indicate that Gi=o may be involved in the inhibitory mecha-
nism of the U-opioid agonist, U-69593. As such, it is possible
that U-69593 inhibits AD via Gi=o, which leads to an inhibi-
tion of the cAMP/PKA pathway. This in turn results in the
inhibition of TH enzyme activity and TH synthesis.
While naloxone and nor-BNI completely abolished the in-
hibitory e¡ect of U-69593 on nicotine-induced cAMP produc-
tion, PTX only partially abolished this inhibitory e¡ect of
Fig. 3. E¡ect of U-69593 (U-opioid agonist) on nicotine-induced
cAMP production. (a) PC12 cells were incubated with various con-
centrations (1 nM^1 WM) of U-69593, DPDPE and DAGO (U-,
N- and W-opioid antagonists, respectively) for 10 min. (b) PC12 cells
were incubated for 10 min with U-69593 (1 WM) in the presence of
PTX (100 ng/ml) or naloxone (1 WM) or nor-BNI (100 nM), as indi-
cated. Then intracellular cAMP was subjected to EIA as described
in Section 2. Control experiments were done with nicotine (10 WM)
alone. *Signi¢cantly di¡erent (P6 0.05) from control.
Fig. 4. E¡ects of U-69593 (U-opioid agonist) on TH protein level.
(a) PC12 cells were incubated for 24 h with U-69593 (10 nM^1
WM). Then, the TH protein level was measured by Western blot as
described in Section 2. (b) The values represent the means þ S.D.
(n = 4). Control experiments were done with nicotine (10 WM) alone.
*Signi¢cantly di¡erent (P6 0.05) from controls.
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U-69593 (Fig. 3b). The reasons for this di¡erence are unclear.
However, one possible explanation for this di¡erence is that
inhibitory mechanisms other than that of Gi=o, such as the
PTX-insensitive G-protein, as suggested by Ozawa et al.
may contribute to the inhibitory e¡ects of U-69593 [26]. Fur-
ther studies (i.e. test the level of ADP ribosylation) will be
needed to clarify this point.
The e¡ective concentrations of U-69593 that we described
in the present study (far greater than its Kd value in PC12 cells
(2.18 nM) [27]) are rather high. This indicates that the e¡ects
of U-69593 we observed here are not mediated by an opioid
receptor, which is consistent with the inhibitory e¡ect of U-
50488 (another U-agonist) [14,28]. However, Venihaki et al.
[13] demonstrated that U-69593 inhibited nicotine-induced
catecholamine secretion in PC12 cells at high concentrations,
which is comparable to that observed in our study. They also
showed that the inhibitory e¡ect of U-69593 was reversed by
nalaxone and claimed that the U-69593 e¡ects were mediated
by opioid receptors, which is in agreement with our study.
The precise reasons for these discrepancies are unclear and
further studies will be needed to determine whether opioid
receptors are involved in the inhibitory mechanisms of U-
69593. Also, the e¡ect of using di¡erent drugs (U-69593 vs.
U-50488) should be considered.
It was previously reported [13] that U-69593 did not alter
intracellular catecholamine levels in PC12 cells and that the
anti-cholinergic e¡ects of U-opioids were due to the inhibition
of catecholamine release rather than biosynthesis. While this
obviously disagrees with the results presented here, the rea-
sons for this di¡erence are unclear. Venihaki et al. [13] did not
examine the e¡ects of U-69593 on the TH enzyme activity and
TH synthesis in PC12 cells. Also, di¡erences in exposure time
to U-69593 (24 h vs. 12 h) could be signi¢cant.
In contrast to the inhibitory e¡ects of U-69593, DPDPE
and DAGO (N- and W-opioid agonists, respectively) had no
signi¢cant e¡ects on the nicotine-induced TH enzyme activity
and TH synthesis, con¢rming that N- and W-opioids play a
minimal role in the anti-cholinergic e¡ect in chroma⁄n cells
[13,14].
Kampa et al. [12] recently demonstrated that the U-sites
were the dominant opioid binding sites in human pheochro-
mocytomas. Combining our ¢ndings presented here with pre-
vious studies, it would appear that U-opioid may inhibit cat-
echolamine biosynthesis as well as catecholamine release in
human pheochromocytomas. Alternatively, di¡erences in tis-
sue content of U-opioid peptide may contribute to the clinical
manifestations of pheochromocytomas, by the inhibition of
catecholamine biosynthesis [10,11].
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